3 news items
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BYSI
3 May 24
a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy. Dr. Lin acquired his M.D
BeyondSpring Doses First Patient With Pembrolizumab, Plinabulin Plus Etoposide/Platinum In A Phase 2 Investigator-Initiated Study Of First-Line Extensive-Stage Small-Cell Lung Cancer
BYSI
25 Mar 24
Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate (ORR) is high (around
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BYSI
25 Mar 24
response rate (ORR) is high (around 60-65%), median progression free survival (PFS) remains low (< 6 months), with median overall survival at 10-13
- Prev
- 1
- Next